18F-fluoromethylcholine (FCho), 18F-fluoroethyltyrosine (FET), and 18F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: A PET study

Nuclear Medicine and Biology

Volumn 42, Issue 1, 2015, Pages 38-45

  Bolcaen, Julie ^a   Descamps, Benedicte ^b   Deblaere, Karel ^a   Boterberg, Tom ^a   De Vos Pharm, Filip ^b   Kalala, Jean Pierre ^a   Van den Broecke, Caroline ^a   Decrock, Elke ^b   Leybaert, Luc ^b   Vanhove, Christian ^b   Goethals, Ingeborg ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

18F FCho; 18F FDG; 18F FET; Glioblastoma; PET; Radiation necrosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROETHYLTYROSINE F 18; FLUOROMETHYLCHOLINE F 18; GADOTERATE MEGLUMINE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (18F)FLUOROETHYLTYROSINE; CHOLINE; FLUOROMETHYLCHOLINE; TRACER; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER MORPHOLOGY; CANCER RECURRENCE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; FRONTAL CORTEX; GLIOBLASTOMA; IMAGE ANALYSIS; IMAGE QUALITY; IMAGE RECONSTRUCTION; INTERMETHOD COMPARISON; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIATION NECROSIS; RADIODIAGNOSIS; RAT; RAT MODEL; TUMOR CELL INOCULATION; TUMOR DIAGNOSIS; VOXEL BASED MORPHOMETRY; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; DIAGNOSTIC USE; NECROSIS; PATHOLOGY; RADIATION INJURIES; RECURRENT DISEASE; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHOLINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOBLASTOMA; NECROSIS; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; RADIATION INJURIES; RADIOACTIVE TRACERS; RADIOPHARMACEUTICALS; RATS; RECURRENCE; TYROSINE;

EID: 84920459313     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.07.006     Document Type: Article

References (38)

1. Omuro A., DeAngelis L.M. Glioblastoma and other malignant gliomas: a clinical review. J Am Med Assoc 2013, 310(17):1842-1850.
2. Anton K., Baehring J.M., Mayer T. Glioblastoma multiforme: overview of current treatment and future perspectives. Hematol Oncol Clin North Am 2012, 26(4):825-853.
3. Ruggieri P.M. Magnetic resonance imaging. High-Grade gliomas diagnosis and treatment 2007, 105-132. Humana Press Inc., Totowa. G.H. Barnett (Ed.).
4. Stupp R., Dietrich P.Y., Ostermann Kraljevic S., Pica A., Maillard I., Maeder P., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20:1375-1382.
5. Siu A., Wind J.J., Iorgulescu J.B., Chan T.A., Yamada Y., Sherman J.H. Radiation necrosis following treatment of high grade glioma-a review of the literature and current understanding. Acta Neurochir 2012, 154(2):191-201.
6. Ruben J.D., Dally M., Bailey M., Smith R., McLean C., Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006, 65(2):499-508.
7. Langleben D.D., Segall G.M. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000, 41:1861-1867.
8. Rahmathulla G., Marko N.F., Weil R.J. Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations. J Clin Neurosci 2013, 20(4):485-502.
9. Lizarraga K.J., Allen-Auerbach M., Czernin J., Desalles A.A., Yong W.H., Phelps M.E., et al. 18F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med 2014, 55(1):30-36.
10. Bobek-Billewicz B., Stasik-Pres G., Majchrzak H., Zarudzki T. Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy. Folia Neuropathol 2010, 48(2):81-92.
11. Alexiou G.A., Tsiouris S., Kyritsis A.P., Voulgaris S., Argyropoulou M.I., Fotopoulos A.D. Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities. J Neurooncol 2009, 95:1-11.
12. Spaeth N., Wyss M.T., Weber B., Scheidegger S., Lutz A., Verwey J., et al. Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence. J Nucl Med 2004, 45:1931-1938.
13. Van Laere K., Ceyssens S., Van Calenbergh F., de Groot T., Menten J., Flamen P., et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 2005, 32:39-51.
14. Chao S.T., Suh J.H., Raja S., Lee S.Y., Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001, 96:191-197.
15. Doyle W.K., Budinger T.F., Valk P.E., Levin V.A., Gutin P.H. Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr 1987, 11(4):563-570.
16. Kahn D., Follett K.A., Bushnell D.L., Nathan M.A., Piper J.G., Madsen M., et al. Diagnosis of recurrent brain tumor: value of 201T1 SPECT vs 18F-fluorodeoxyglucose PET. Am J Roentgenol 1994, 163:1459-1465.
17. Ricci P.E., Karis J.P., Heiserman J.E., Fram E.K., Bice A.N., Drayer B.P. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?. Am J Neuroradiol 1998, 19:407-413.
18. Kim Y.H., Oh S.W., Lim Y.J., Park C.K., Lee S.H., Kang K.W., et al. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg 2010, 112(9):758-765.
19. Pöpperl G., Götz C., Rachinger W., Schnell O., Gildehaus F.J., Tonn J.C., et al. Serial 0-(2-(18F)fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 2006, 33:792-800.
20. Mehrkens J.H., Pöpperl G., Rachinger W., Herms J., Seelos K., Tatsch K., et al. The positive predictive value of 0-(2-(18F)fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol 2008, 88:27-35.
21. Tan H., Chen L., Guan Y., Lin X. Comparison of MRI, F-18 FDG and 11C-Choline PET/CT for their potentials in differentiating brain tumor recurrence from brain tumor necrosis following radiotherapy. Clin Nucl Med 2011, 36(11):978-981.
22. Rachinger W., Goetz C., Pöpperl G., Gildehaus F.J., Kreth F.W., Holtmannspötter M., et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005, 57(3):505-511.
23. Galldiks N., Stoffels G., Filss C.P., Piroth M.D., Sabel M., Ruge M.I., et al. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med 2012, 53(9):1367-1374.
24. Spaeth N., Wyss M.T., Pahnke J., Biollaz G., Lutz A., Goepfert K., et al. Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L-tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat. Eur J Nucl Med Mol Imaging 2006, 33(6):673-682.
25. Mertens K., Bolcaen J., Ham H., Deblaere K., Van den Broecke C., Boterberg T., et al. The optimal timing for imaging brain tumours and other brain lesions with F-18 labelled fluoromethylcholine: a dynamic PET study. Nucl Med Commun 2012, 33(9):954-959.
26. Schneider C.A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012, 9:671-675.
27. Barth R.F., Kaur B. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol 2009, 94:299-312.
28. Brat D.J., Prayson R.A., Rycken T.C., Olson J.J. Diagnosis of malignant glioma: role of neuropathology. J Neurooncol 2008, 89:287-311.
29. Mertens K., Ham H., Deblaere K., Kalala J.P., Van den Broecke C., Slaets D., et al. Distribution patterns of 18F-labelled fluoromethylcholine in normal structures and tumors of the head: a PET/MRI evaluation. Clin Nucl Med 2012, 37(8):196-203.
30. The Cancer Genome Atlas Research Network Comprehensive genomic characterisation defines human glioblastoma genes and core pathways. Nature 2008, 455(7216):1061-1068.
31. Yoshii Y. Pathological review of late cerebral radionecrosis. Brain Tumor Pathol 2008, 25:51-58.
32. Wang S., Tryggestad E., Zhou T., Armour M., Wen Z., Fu D.X., et al. Assessment of MRI parameters as imaging biomarkers for radiation necrosis in the rat brain. Int J Radiat Oncol Biol Phys 2012, 83(3):431-436.
33. Hideghety K., Plangár I., Mán I., Fekete G., Nagy Z., Volford G., et al. Development of a small-animal focal brain irradiation model to study radiation injury and radiation-injury modifiers. Int J Radiat Biol 2013, 89(8):645-655.
34. Kumar S., Arbab A.S., Jain R., Kim J., deCarvalho A.C., Shankar A., et al. Development of a novel animal model to differentiate radiation necrosis from tumor recurrence. J Neurooncol 2012, 108(3):411-420.
35. Verhaegen F., Granton P., Tryggestad E. Small animal radiotherapy research platforms. Phys Med Biol 2011, 56:R55-R83.
36. Langen K.J., Hamacher K., Weckesser M., Floeth F., Stoffels G., Bauer D., et al. O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2006, 33:287-294.
37. Hawkins B.T., Egleton R.D. Fluorescence imaging of blood-brain barrier disruption. J Neurosci Methods 2006, 15:1262-1267.
38. Rapoport S.I. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 2000, 20(2):217-230.